Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Fibrotic disease and the T(H)1/T(H)2 paradigm Wynn TANat Rev Immunol 2004[Aug]; 4 (8): 583-94Tissue fibrosis (scarring) is a leading cause of morbidity and mortality. Current treatments for fibrotic disorders, such as idiopathic pulmonary fibrosis, hepatic fibrosis and systemic sclerosis, target the inflammatory cascade, but they have been widely unsuccessful, largely because the mechanisms that are involved in fibrogenesis are now known to be distinct from those involved in inflammation. Several experimental models have recently been developed to dissect the molecular mechanisms of wound healing and fibrosis. It is hoped that by better understanding the immunological mechanisms that initiate, sustain and suppress the fibrotic process, we will achieve the elusive goal of targeted and effective therapeutics for fibroproliferative diseases.|Animals[MESH]|Chemokines/metabolism[MESH]|Fibroblasts/metabolism[MESH]|Fibrosis/*immunology/metabolism/therapy[MESH]|Humans[MESH]|Interleukin-13/metabolism[MESH]|Macrophages/metabolism[MESH]|Th1 Cells/*immunology/metabolism[MESH]|Th2 Cells/*immunology/metabolism[MESH]|Transforming Growth Factor beta/metabolism[MESH] |